4.7 Article

Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Infectious Diseases

Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients

June Young Chun et al.

Summary: The study found that administering a live HZ vaccine 2 years post-HSCT is both immunogenic and safe.

BMC INFECTIOUS DISEASES (2021)

Article Hematology

Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation

Emily Baumrin et al.

Summary: This study evaluated the safety and reactogenicity of the non-live adjuvanted recombinant zoster vaccine (RZV) in allogeneic hematopoietic cell transplantation (HCT) recipients, finding that RZV was safe, tolerable, and did not increase rates of graft-versus-host disease (GVHD). Future clinical trials are needed to determine the immunogenicity and efficacy of RZV in this population.

BLOOD ADVANCES (2021)

Article Immunology

Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients

Monika Lindemann et al.

Summary: The cellular response to SARS-CoV-2 vaccination and infection in HSCT recipients remains unclear. The study found that HSCT patients vaccinated twice had significantly higher SARS-CoV-2 IgG antibodies compared to pre-vaccination. However, their ELISpot responses were reduced to less than 33% of controls. Female patients and healthy controls showed higher antibody responses post-vaccination, while cellular immunity was diminished in patients regardless of sex.

VACCINES (2021)

Article Immunology

Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays

Irene Cassaniti et al.

Summary: This study aimed to investigate the changes in VZV-specific T-cell response among solid organ transplant recipients. The results showed that VZV-seropositive healthy subjects exhibited stronger responses against VZV, while the VZV-specific T-cell response in transplant recipients significantly decreased at 60 days post-transplant, mainly due to high levels of immunosuppression.

VACCINES (2021)

Article Biochemistry & Molecular Biology

The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients

Monika Lindemann et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Review Infectious Diseases

Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections

A. Sauerbrei

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2016)

Article Immunology

The cytokine profile of human NKT cells and PBMCs is dependent on donor sex and stimulus

Hannah Bernin et al.

MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2016)

Review Immunology

Sex differences in immune responses

Sabra L. Klein et al.

NATURE REVIEWS IMMUNOLOGY (2016)

Article Geriatrics & Gerontology

Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study

Svetlana Di Benedetto et al.

BIOGERONTOLOGY (2015)

Article Infectious Diseases

Incidence of herpes zoster and its complications in Germany, 2005-2009

Kathrin Hillebrand et al.

JOURNAL OF INFECTION (2015)

Article Medicine, General & Internal

Zoster: Manifestationsformen an der Haut, Komplikationen und Therapie

G. Gross

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2008)

Article Immunology

Humoral and cellular immunity to varicella-zoster virus: An overview

Ann M. Arvin

JOURNAL OF INFECTIOUS DISEASES (2008)

Editorial Material Medicine, General & Internal

Aging, immunity, and the varicella-zoster virus

A Arvin

NEW ENGLAND JOURNAL OF MEDICINE (2005)